Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease

NCT03289143 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03289143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03289143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 4, 2017
Completion date
January 15, 2021
Enrollment
457 (actual)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease